Dr. Brandon J. Trivax

Dr. Feldman is the director of the NeuroNetwork for Emerging Therapies at Michigan Medicine and the ALS Center of Excellence at Michigan Medicine. The latter includes the Pranger ALS Clinic, one of the top multidisciplinary clinics caring for those suffering from amyotrophic lateral sclerosis (ALS). She serves as the University of Michigan James W. Albers Distinguished University Professor and the Russell N. DeJong Professor of Neurology at Michigan Medicine. Dr. Feldman is one of the world’s leading authorities on neurodegenerative disease.Dr. Feldman is a compassionate and dedicated physician who cares deeply about her patients. She has been recognized for her clinical excellence by numerous organizations and is annually named as one of the “Best Doctors in America.” Her forward-thinking, collaborative, multidisciplinary approach has transformed how neurodegenerative diseases are diagnosed, treated, and prevented.Dr. Feldman has made significant contributions to biomedical research and clinical care in many critical areas of neurodegenerative disease. She has authored over 530 peer-reviewed publications, 74 book chapters, and 5 books on the pathology, diagnosis, and treatment of neurological diseases. Dr. Feldman has been continuously funded by the NIH since 1989 and is currently the principal or co-investigator of numerous clinical trials and grants. She has received numerous awards and honors throughout her remarkable career, including the University of Michigan’s Early Distinguished Career Award, the Distinguished Faculty Achievement Award, and the Distinguished Alumnus Achievement Award. She was also the first woman in 25 years to receive the Robert S. Schwab Award from the American Clinical Neurophysiology Society. In 2022, Dr. Feldman was awarded the University of Michigan Distinguished Professorship, the highest faculty honor at University of Michigan.Dr. Feldman is actively committed to and involved in professional service. She served as President of the Peripheral Nerve Society from 2007-2009 and President of the American Neurological Association (ANA) from 2011-2013. Dr. Feldman is an elected member of the National Academy of Medicine (NAM) and Association of American Physicians, and a Fellow of the American Association for the Advancement of Science. Dr. Feldman is the Editor of the Contemporary Neurology Series and also serves on a number of editorial boards for leading scientific journals, including The Lancet Neurology, Nature Reviews Neurology, JAMA Neurology and Journal of Neurology, Neurosurgery and Psychiatry. Dr. Feldman is highly rated in 33 conditions, according to our data. Her clinical expertise encompasses Peripheral Neuropathy, Diabetic Neuropathy, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), and Autonomic Neuropathy. Dr. Feldman is board certified in Neurology and Electrodiagnostic Medicine.

Stephen Goutman, MD, MS is an Associate Professor in the Department of Neurology and Director of the Amyotrophic Lateral Sclerosis Clinic and ALS Center of Excellence at Michigan Medicine. After obtaining a degree in neuroscience at the Johns Hopkins University (Baltimore, MD), Dr. Goutman completed his medical degree at the University of Chicago Pritzker School of Medicine (Chicago, IL) and his neurology residency and neuromuscular fellowship at Cleveland Clinic (Cleveland, OH). He received a Master’s in Clinical Research Design and Statistical Analysis at the University of Michigan (Ann Arbor, MI).Dr. Goutman evaluates and treats patients with neuromuscular diseases and is interested in diseases such as myasthenia gravis and muscle diseases. His area of expertise is amyotrophic lateral sclerosis (ALS)/Lou Gehrig’s Disease where his focus is delivering comprehensive and compassionate care. He is Director of the ALS Clinic, an ALS Association Certified Center of Excellence (http://www.umich-als.org/), where he leads a team of providers that care for persons with ALS and their families. Dr. Goutman is inspired by his patients and thus aims to provide the highest level of care.Dr. Goutman’s research is focused on identifying causes of and treatments for ALS. He leads research efforts that received funding by the National Institutes of Health and the Centers for Disease Control aimed at identifying environmental risk factors and causes of ALS (https://umhealthresearch.org/#studies/HUM00028826) and showed, in an article that received widespread attention, a connection between ALS and organochlorine pesticides (https://jamanetwork.com/journals/jamaneurology/fullarticle/2519875). Dr. Goutman also helps direct the University of Michigan ALS Biorepository which provides essential resources to ALS researchers within and external to the University of Michigan enabling studies into areas of ALS genetics, epigenetics, and immunology.Dr. Goutman is a site principal investigator of several multisite clinical trials focused on identifying new ALS treatments and causes and is an active participant with the Northeast ALS Consortium (NEALS) to improve care for ALS. He received a 2016 Young Investigator Award by the World Federation of Neurology Research Group on Motor Neuron Diseases. Dr. Goutman is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, Spinal Muscular Atrophy (SMA), and Spinal and Bulbar Muscular Atrophy. Dr. Goutman is board certified in Neurology, Neuromuscular Medicine, and Electrodiagnostic Medicine.

Amro Stino, MD is an Associate Professor in the Department of Neurology in the University of Michigan Medical School, Division of Neuromuscular Medicine. Dr. Stino has expertise in the treatment of neuromuscular disorders, with special clinical and research interest in the care of patients with acquired peripheral neuropathy.A native of Ann Arbor, MI and a product of Ann Arbor schools, Dr. Stino went on to pursue a Bachelor of Science degree in Brain, Behavioral, and Cognitive Sciences from the University of Michigan, Ann Arbor, which he completed in 2006. He received his medical degree from Wayne State University, School of Medicine in Detroit, MI in 2010 and completed a transitional year internship at St. Joseph Mercy Hospital, in Ann Arbor, MI. He then completed his neurology residency training at the Wayne State University, School of Medicine – Detroit Medical Center, followed by a fellowship in clinical neurophysiology / neuromuscular medicine at The Mayo Clinic in Arizona. He joined The Ohio State University faculty in 2015 as Director of the Peripheral Neuropathy Clinic and Autonomic Lab. During his time there, he oversaw expansion of diagnostic testing and clinical operations of both, helping provide more comprehensive neuropathy care for central and southern Ohio patients seeking multi-disciplinary acquired neuropathy care. He helped obtain CIDP and CMT center of excellence accreditation. He joined the University of Michigan faculty in 2019 as Director of the Peripheral Neuropathy clinic and Co-director of the Autonomic Lab. Currently, he serves as site principal investigator on multi-center studies in the realms of metabolic and autoimmune neuropathy. He is presently conducting an investigator initiated phase 1b trial on the novel use of Lenalidomide in anti-MAG neuropathy.Dr. Stino is an advocate for patient awareness and education in autoimmune neuropathy and serves as physician liaison for the GBS-CIDP foundation, with whom he was interviewed on Good Day Columbus as part of GBS-CIDP awareness month. He also takes great interest in helping patients tackle peripheral neuropathy care in an evidence based fashion, particularly as it pertains to pain control.Dr. Stino enjoys working alongside and mentoring neuromuscular fellows, neurology residents, and medical students who rotate with him in clinic or inpatient service. He serves on the Peripheral Nerve Society Junior Board, which helps organize an annual educational course for attendees. His online videos on autoimmune neuropathy, small fiber neuropathy, and postural tachycardia syndrome have been viewed by thousands.He remains a dedicated Wolverine, despite having worked down south. Dr. Stino is highly rated in 34 conditions, according to our data. His clinical expertise encompasses Chronic Inflammatory Demyelinating Polyneuropathy, Peripheral Neuropathy, Chronic Polyradiculoneuritis, and Familial Dysautonomia. Dr. Stino is board certified in Neurology, Clinical Neurophysiology, and Electrodiagnostic Medicine.